Literature DB >> 2709110

Correlation of histopathological features and proliferative potential of gliomas.

I M Germano1, M Ito, K G Cho, T Hoshino, R L Davis, C B Wilson.   

Abstract

One hundred fifty-two intracranial gliomas of various types were reviewed in order to correlate the histopathological features with the proliferative potential of each tumor as reflected by the bromodeoxyuridine (BUdR) labeling index (LI). Patients undergoing surgical removal of gliomas were given a 30-minute intravenous infusion of BUdR (150 to 200 mg/sq m) to label S-phase tumor cells. The tumor specimens were stained immunohistochemically for BUdR and processed for routine histopathological diagnosis. The BUdR LI was calculated as the percentage of labeled cells among cells analyzed. Twenty-seven histological features in three categories (degenerative, vascular, and cellular changes) were considered. A significantly higher BUdR LI (p less than 0.05) was found in tumors with necrosis than in those without this feature; tumors with both coagulative and liquefactive necrosis had the highest BUdR LI (p less than 0.05). Increased vascularity was also associated with a higher BUdR LI (p less than 0.05). Although tumors with abnormal mitotic figures had a significantly higher BUdR LI than those without, the number of mitoses did not correlate with a higher BUdR LI. These results suggest that the number of mitoses is not a good indicator of tumor growth rate. Necrosis and increased vascularity should be heavily weighted in predicting the proliferative potential of individual gliomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709110     DOI: 10.3171/jns.1989.70.5.0701

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density.

Authors:  R Miralbell; M Tolnay; S Bieri; A Probst; A P Sappino; W Berchtold; M S Pepper; G Pizzolato
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

2.  Oligoastrocytomas: a clinicopathological study of 52 cases.

Authors:  H G Krouwer; S G van Duinen; W Kamphorst; P van der Valk; A Algra
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

3.  Cell kinetic analysis in recurrent neuro-epithelial tumours.

Authors:  E Gömöri; I Mészáros; G Méhes; T Dóczi; L Pajor
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 4.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Growth factor receptors signaling in glioblastoma cells: therapeutic implications.

Authors:  Mia Carapancea; Oana Alexandru; Ani S Fetea; Laura Dragutescu; Juan Castro; Ada Georgescu; A Popa-Wagner; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2008-11-30       Impact factor: 4.130

6.  Proliferative potential and outcome in pediatric astrocytic tumors.

Authors:  M D Prados; H G Krouwer; M S Edwards; P H Cogen; R L Davis; T Hoshino
Journal:  J Neurooncol       Date:  1992-07       Impact factor: 4.130

7.  "Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy.

Authors:  Elisabetta Mormone; Sunita D'Sousa; Vera Alexeeva; Maria M Bederson; Isabelle M Germano
Journal:  Stem Cells Dev       Date:  2014-07-25       Impact factor: 3.272

8.  Immunohistochemical markers for prognosis of anaplastic astrocytomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

9.  A correlative study of in vivo and in vitro labeling index using bromodeoxyuridine in human brain tumors.

Authors:  K Kharbanda; A K Dinda; C Sarkar; A K Karak; R Dhir; M Mathur; S Roy
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours.

Authors:  M B Parliament; M J Allalunis-Turner; A J Franko; P L Olive; R Mandyam; C Santos; B Wolokoff
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.